Sangamo Therapeutics (NASDAQ: SGMO) recently thrilled investors with an update for its experimental gene therapy. It looks like SB-525 can help people with a rare bleeding disorder called hemophilia A, but it isn't the only potential new treatment for this condition.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,